PL3903774T3 - N,n-bis-2-merkaptoetyloizoftalamid do leczenia chorób neurodegeneracyjnych - Google Patents

N,n-bis-2-merkaptoetyloizoftalamid do leczenia chorób neurodegeneracyjnych

Info

Publication number
PL3903774T3
PL3903774T3 PL21180847.2T PL21180847T PL3903774T3 PL 3903774 T3 PL3903774 T3 PL 3903774T3 PL 21180847 T PL21180847 T PL 21180847T PL 3903774 T3 PL3903774 T3 PL 3903774T3
Authority
PL
Poland
Prior art keywords
mercaptoethylisopthalamide
bis
treatment
neurodegenerative diseases
neurodegenerative
Prior art date
Application number
PL21180847.2T
Other languages
English (en)
Inventor
Boyd Eugene HALEY
Ragnar Axel Theodor KLINGBERG
Original Assignee
Emeramed Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emeramed Limited filed Critical Emeramed Limited
Publication of PL3903774T3 publication Critical patent/PL3903774T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL21180847.2T 2014-05-30 2015-05-29 N,n-bis-2-merkaptoetyloizoftalamid do leczenia chorób neurodegeneracyjnych PL3903774T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1409662.2A GB2526623A (en) 2014-05-30 2014-05-30 New pharmaceutical use

Publications (1)

Publication Number Publication Date
PL3903774T3 true PL3903774T3 (pl) 2023-03-13

Family

ID=51214502

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15733860T PL3148588T3 (pl) 2014-05-30 2015-05-29 N,n-bis-2-merkaptoetyloizoftalamid do leczenia choroby parkinsona
PL21180847.2T PL3903774T3 (pl) 2014-05-30 2015-05-29 N,n-bis-2-merkaptoetyloizoftalamid do leczenia chorób neurodegeneracyjnych

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL15733860T PL3148588T3 (pl) 2014-05-30 2015-05-29 N,n-bis-2-merkaptoetyloizoftalamid do leczenia choroby parkinsona

Country Status (17)

Country Link
US (4) US20170202791A1 (pl)
EP (2) EP3903774B1 (pl)
CY (1) CY1124509T1 (pl)
DK (2) DK3148588T3 (pl)
ES (2) ES2882977T3 (pl)
FI (1) FI3903774T3 (pl)
GB (1) GB2526623A (pl)
HR (2) HRP20230105T1 (pl)
HU (2) HUE060927T2 (pl)
LT (2) LT3903774T (pl)
MA (2) MA40065B1 (pl)
PL (2) PL3148588T3 (pl)
PT (2) PT3903774T (pl)
RS (2) RS62095B1 (pl)
SI (2) SI3148588T1 (pl)
SM (2) SMT202100453T1 (pl)
WO (1) WO2015181567A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005057D0 (en) 2020-04-06 2020-05-20 Emeramed Ltd New Use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586600B2 (en) 2000-12-06 2003-07-01 University Of Kentucky Research Foundation Multidentate sulfur-containing ligands
US8349359B2 (en) * 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
US8950583B2 (en) 2008-12-06 2015-02-10 Ermes Medical Company Limited Method to remove heavy metals from a mammal
JP2013505963A (ja) 2009-09-28 2013-02-21 ユニヴァーシティ オブ ケンタッキー リサーチ ファウンデイション 汚染された環境から元素を除去するチオール含有化合物およびその使用方法
US8575218B2 (en) 2009-09-28 2013-11-05 The University Of Kentucky Research Foundation Thiol-containing compounds for the removal of elements from tissues and formulations therefor
US20110237776A1 (en) 2010-03-25 2011-09-29 Haley Boyd E Aromatic compounds with sulfur containing ligands
US8426368B2 (en) 2010-03-25 2013-04-23 The University Of Kentucky Research Foundation Method of ameliorating oxidative stress and supplementing the diet

Also Published As

Publication number Publication date
ES2882977T3 (es) 2021-12-03
US20230013704A1 (en) 2023-01-19
HRP20230105T1 (hr) 2023-03-17
US12128017B2 (en) 2024-10-29
WO2015181567A1 (en) 2015-12-03
HUE055575T2 (hu) 2021-12-28
SI3903774T1 (sl) 2023-03-31
PT3903774T (pt) 2022-12-23
US11628151B2 (en) 2023-04-18
LT3148588T (lt) 2021-08-10
RS63859B1 (sr) 2023-01-31
HUE060927T2 (hu) 2023-04-28
PT3148588T (pt) 2021-07-15
DK3903774T3 (da) 2023-01-16
EP3148588B1 (en) 2021-06-23
FI3903774T3 (fi) 2023-04-12
LT3903774T (lt) 2023-01-10
MA54630A (fr) 2021-11-03
CY1124509T1 (el) 2022-07-22
US20180250247A1 (en) 2018-09-06
EP3903774B1 (en) 2022-11-09
SI3148588T1 (sl) 2022-01-31
MA40065A (fr) 2021-05-19
US20170202791A1 (en) 2017-07-20
HRP20211309T1 (hr) 2021-11-26
RS62095B1 (sr) 2021-08-31
MA54630B1 (fr) 2023-01-31
SMT202100453T1 (it) 2021-09-14
EP3148588A1 (en) 2017-04-05
MA40065B1 (fr) 2021-09-30
PL3148588T3 (pl) 2021-12-13
EP3903774A1 (en) 2021-11-03
GB201409662D0 (en) 2014-07-16
DK3148588T3 (en) 2021-07-26
SMT202300015T1 (it) 2023-03-17
GB2526623A (en) 2015-12-02
US20220287994A1 (en) 2022-09-15
ES2938080T3 (es) 2023-04-04

Similar Documents

Publication Publication Date Title
IL283561B (en) Methods for treating ocular diseases
IL296080B1 (en) Method for treating cancer
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
LT3556775T (lt) Anti-lag-3 antikūnai, skirti hematologinių piktybinių susirgimų gydymui
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3191144T3 (da) Medicinsk forbinding
HUE059694T2 (hu) Készítmény rák kezelésére
LT3169328T (lt) Chinolino dariniai, skirti uždegiminių ligų gydymui
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
HRP20190194T1 (hr) 17a,21-diesteri korteksolona, namijenjeni liječenju tumora
DK3231444T3 (da) Ny behandling
EP3215219C0 (en) SKIN TREATMENT SYSTEM
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
BR112016022976A2 (pt) Métodos para o tratamento de hcv
LT3210973T (lt) Heteroarilo junginiai, skirti akių ligų gydymui
PL3134119T3 (pl) Leczenie nowotworu
EP3157631A4 (en) Neurodegenerative disease treatment
EP3362091A4 (en) COMBINATION THERAPY
SI3188599T1 (sl) Zdravljenje na osnovi anamorelina
DK3393478T3 (da) Kombinationsterapi
DK3166473T3 (da) Oftalmoskoper
EP3493821A4 (en) METHOD OF TREATING THE RESPIRATORY TRACT
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
DK3096775T5 (da) SOCS-mimetika til behandling af sygdomme
DK3855181T3 (da) Forbindelser til behandling af lipofuscinrelaterede sygdomme